Citations

Clear

6273 citation(s) found for "To, Andrew".

In-hospital safety outcomes of left atrial appendage occlusion in octogenarians and nonagenarians
Ismayl, Mahmoud , Ahmed, Hasaan , Goldsweig, Andrew M. , Freeman, James V. , Goldsweig, Andrew M , Freeman, James V , Ismayl, Mahmoud , Alkhouli, Mohamad

Mayo Clinic

Europace | February 22, 2024 | Volume: 26 | Issue: 3 | Pages: No page available

10.1093/europace/euae055 | PMID 38391186 Get It

Abstract Aims Data on safety outcomes of left atrial appendage occlusion (LAAO) in elderly patients are limited. This study aimed to compare the outcomes of LAAO between octogenarians (age 80–89) and nonagenarians (age ≥90) vs. younger patients (age ≤79). Methods and results We conducted a retrospective cohort study using the National Inpatient Sample database to identify patients hospitalized for LAAO from 2016 to 2020 and to compare in-hospital safety outcomes in octogenarians and nonagenarians vs. younger patients. The primary outcome was a composite of in-hospital all-cause mortality or stroke. Secondary outcomes included procedural complications, length of stay (LOS), and total costs. Outcomes were determined using logistic regression models. Among 84 140 patients hospitalized for LAAO, 32.9% were octogenarians, 2.8% were nonagenarians, and 64.3% were ≤79 years of age. Over the study period, the volume of LAAO increased in all age groups (all Ptrend < 0.01). After adjustment for clinical and demographic factors, octogenarians and nonagenarians had similar odds of in-hospital all-cause mortality or stroke [adjusted odds ratio (aOR) 1.41, 95% confidence interval (CI) 0.93–2.13 for octogenarians; aOR 1.69, 95% CI 0.67–3.92 for nonagenarians], cardiac tamponade, acute kidney injury, major bleeding, and blood transfusion, in addition to similar LOS and total costs compared with younger patients (all P > 0.05). However, octogenarians and nonagenarians had higher odds of vascular complications compared with younger patients (aOR 1.47, 95% CI 1.08–1.99 for octogenarians; aOR 1.60, 95% CI 1.18–2.97 for nonagenarians). Conclusion Octogenarians and nonagenarians undergoing LAAO have a similar safety profile compared with clinically similar younger patients except for higher odds of vascular complications.
Unresponsiveness of Activated Partial Thromboplastin Time to Bivalirudin in Adults Receiving Extracorporeal Membrane Oxygenation
Jatis, Andrew J. , Nei, Scott D. , Seelhammer, Troy G. , Mara, Kristin C. , Wieruszewski, Patrick M. , Mara, Kristin C , Wieruszewski, Patrick M

Mayo Clinic

ASAIO Journal | February 22, 2024 | Volume: 70 | Issue: 8 | Pages: 675-681

10.1097/mat.0000000000002172 | PMID 38387004 Get It

Activated partial thromboplastin time (aPTT) is the standard for monitoring bivalirudin but demonstrates a nonlinear response at higher drug concentrations. The objective of this study was to assess the relationship between bivalirudin dose and aPTT in patients receiving extracorporeal membrane oxygenation (ECMO) to determine a threshold where aPTT unresponsiveness occurs. Two hundred fourteen adults receiving bivalirudin during ECMO between 2018 and 2022 were included. Piecewise regression in a linear mixed effects model was used to determine a bivalirudin dose threshold of 0.21 mg/kg/hr for aPTT unresponsiveness. For doses of less than 0.21 mg/kg/hr (n = 135), every 0.1 mg/kg/hr dose increase led to an aPTT increase of 11.53 (95% confidence interval [CI] = 9.85–13.20) seconds compared to only a 3.81 (95% CI = 1.55–6.06) seconds increase when dose was greater than or equal to 0.21 mg/kg/hr (n = 79) (p interaction < 0.001). In multivariable logistic regression, venovenous configuration (odds ratio [OR] = 2.83, 95% CI = 1.38–5.77) and higher fibrinogen concentration (OR = 1.22, 95% CI = 1.05–1.42) were associated with greater odds of unresponsiveness, whereas older age (OR = 0.79, 95% CI = 0.63–0.98), kidney dysfunction (OR = 0.48, 95% CI = 0.25–0.92), and a higher baseline aPTT (OR = 0.89, 95% CI = 0.82–0.97) were associated with lower odds. Alternative methods are necessary to ascertain bivalirudin’s hemostatic impact when doses exceed 0.21 mg/kg/hr during ECMO.
The Association of Thromboembolic Complications with the Use of Tranexamic Acid for Resection of Intracranial Meningioma
Nguyen, Brandon , Dousse, Dontre, Harris, Mark, Brown, Nolan J. , Nguyen, Andrew, Pennington, Zach , Gendreau, Julian , Dousse, Dontre', Zhang, Angie , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 21, 2024 | Volume: 85 | Issue: S 01 | Pages: S1-S398

10.1055/s-0044-1780144 Get It

Evaluation of Intraoperative Fluoroscopic Techniques to Estimate Femoral Rotation: A Cadaveric Study
Ivanov, David , Welby, John P. , Khanna, Ankur , Barlow, Jonathan D. , Sems, S.A. , Torchia, Michael E., Ivanov, David V, Sems, S Andrew, Yuan, Brandon J. , Barlow, Jonathan D

Mayo Clinic

Journal of Orthopaedic Trauma | February 21, 2024 | Volume: 38 | Issue: 5 | Pages: 279-284

10.1097/bot.0000000000002790 | PMID 38381135 Get It

OBJECTIVES: To compare three fluoroscopic methods for determining femoral rotation. METHODS: Native femoral version was measured by computed tomography in 20 intact femurs from 10 cadaveric specimens. Two Steinmann pins were placed into each left femur above and below a planned transverse osteotomy which was completed through the diaphysis. Four surgeons utilized the true lateral (TL), neck-horizontal angle (NH), and lesser trochanter profile (LTP) techniques to correct the injured femur's rotation using the intact right femur as reference, yielding 120 measurements. Accuracy was assessed by comparing the angle subtended by the two Steinmann pins before and after manipulation and comparing against version measurements of the right femur. RESULTS: Absolute mean rotational error in the fractured femur compared to its uninjured state was 6.0° (95% CI, 4.6-7.5), 6.6° (95% CI, 5.0-8.2), and 8.5° (95% CI, 6.5-10.6) for the TL, NH, and LTP techniques, respectively, without significant difference between techniques (p = 0.100). Compared to the right femur, absolute mean rotational error was 6.6° (95% CI, 1.0-12.2), 6.4° (95% CI, 0.1-12.6), and 8.9° (95% CI, 0.8-17.0) for the TL, NH, and LTP techniques, respectively, without significant difference (p = 0.180). Significantly more femurs were malrotated by >15° using the LTP method compared to the TL and NH methods (20.0% vs 2.5% and 5.0%, p = 0.030). Absolute mean error in estimating femoral rotation of the intact femur using the TL and NH methods compared to CT was 6.6° (95% confidence interval [CI], 5.1-8.2) and 4.4° (95% CI, 3.4-5.4), respectively, with significant difference between the two methods (p = 0.020). CONCLUSIONS: The true lateral (TL), neck-horizontal angle (NH), and the lesser trochanter profile (LTP) techniques performed similarly in correcting rotation of the fractured femur, but significantly more femurs were malrotated by >15° using the LTP technique. This supports preferential use of the TL or NH methods for determining femoral version intraoperatively.
Impact of Unplanned Readmission on Patient-Reported Outcomes After Cervical Spine Surgery: A National Study of 13 355 Patients
Croft, Andrew J. , Vaughan, Wilson E. , Khan, Inamullah , Davidson, Claudia , Bydon, Mohammad, Asher, Anthony L. , Archer, Kristin R. , Berkman, Richard A., Abtahi, Amir M. , Zuckerman, Scott L , Pennings, Jacquelyn S. , Chanbour, Hani , Gardocki, Raymond J. , Stephens, Byron F. , Zuckerman, Scott L.

Mayo Clinic

Neurosurgery | February 21, 2024 | Volume: 95 | Issue: 1 | Pages: 234-249

10.1227/neu.0000000000002872 | PMID 38380924 Get It

BACKGROUND AND OBJECTIVES: Although risk factors for unplanned readmission after cervical spine surgery have been widely reported, less is known about how readmission itself affects patient-reported outcome measures (PROMs). Using the Quality Outcomes Database registry of patients undergoing elective cervical spine surgery, we sought to (1) determine the impact of unplanned readmission on PROMs and (2) compare the effect of specific readmission reasons on PROMs. METHODS: An observational study was performed using a multi-institution, retrospective registry for patients undergoing cervical spine surgery. The occurrence of 90-day unplanned readmission classified into medical, surgical, pain only, and no readmissions was the exposure variable. Outcome variables included 12-month PROMs of Neck Disability Index (NDI), Numeric Rating Scale (NRS)-neck/arm pain, EuroQol-5D (EQ-5D), and patient dissatisfaction. Multivariable models predicting each PROM were built using readmission reasons controlling for demographics, clinical characteristics, and preoperative PROMs. RESULTS: Data from 13 355 patients undergoing elective cervical spine surgery (82% anterior approach and 18% posterior approach) were analyzed. Unplanned readmission within 90 days of surgery occurred in 3.8% patients, including medical (1.6%), surgical (1.8%), and pain (0.3%). Besides medical reasons, wound infection/dehiscence was the most common reason for unplanned readmission for the total cohort (0.5%), dysphagia in the anterior approach (0.6%), and wound infection/dehiscence in the posterior approach (1.5%). Based on multivariable regression, surgical readmission was significantly associated with worse 12-month NDI, NRS-neck pain, NRS-arm pain, EQ-5D, and higher odds of dissatisfaction. Pain readmissions were associated with worse 12-month NDI and NRS-neck pain scores, and worse dissatisfaction. For specific readmission reasons, pain, surgical site infection/wound dehiscence, hematoma/seroma, revision surgery, deep vein thrombosis, and pulmonary embolism were significantly associated with worsened 12-month PROMs. CONCLUSION: In patients undergoing elective cervical spine surgery, 90-day unplanned surgical and pain readmissions were associated with worse 12-month PROMs compared with patients with medical readmissions and no readmissions.
Presenilin‐1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stage
Joseph‐Mathurin, Nelly , Feldman, Rebecca L. , Lu, Ruijin , Shirzadi, Zahra , Toomer, Carmen, Clair, Junie R. Saint, Ma, Yinjiao , Strain, Jeremy F. , Kilgore, Collin , Chen, Charles D., Gordon, Brian A. , Chen, Gengsheng , Hornbeck, Russ C. , Massoumzadeh, Parinaz , Wang, Qing , Li, Yan , Wang, Guoqiao , Keefe, Sarah , Schultz, Stephanie A. , Preboske, Gregory M., Jack, Clifford R. , Ances, Beau M. , Berman, Sarah , Day, Gregory S. , Fox, Nick C. , Fulham, Michael , Ghetti, Bernardino , Johnson, Keith A. , Xiong, Chengjie , Oh, Hwamee , Perrin, Richard J. , Ringman, John M. , Saykin, Andrew J. , Supnet, Charlene , Vöglein, Jonathan , Yakushev, Igor , Morris, John C. , Chhatwal, Jasmeer P. , Network, for the Dominantly Inherited Alzheimer, Jack, Clifford R , Gordon, Brian A , Saykin, Andrew J , Day, Gregory S , Vöglein, Jonathan , Joseph-Mathurin, Nelly , Xiong, Chengjie , Chen, Charles D , Ances, Beau M , Fox, Nick C , Morris, John C , Ghetti, Bernardino F , Supnet-Bell, Charlene , Berman, Sarah , Clair, Junie Saint, McKay, Nicole S. , Friedrichsen, Karl A. , McCullough, Austin , Li, Yan, Cruchaga, Carlos , Llibre‐Guerra, Jorge J. , Allegri, Ricardo , Brooks, William S. , Cash, David M. , Jucker, Mathias , Klunk, William E. , Fougère, Christian la , Niimi, Yoshiki , Reischl, Gerald , Schofield, Peter R. , Su, Yi , Brickman, Adam M. , McDade, Eric , Xiong, Chengjie , Bateman, Randall J. , Benzinger, Tammie L.S. , Network, for the Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia | February 21, 2024 | Volume: 20 | Issue: 4 | Pages: 2680-2697

10.1002/alz.13729 | PMID 38380882 Get It

AbstractINTRODUCTIONAmyloidosis, including cerebral amyloid angiopathy, and markers of small vessel disease (SVD) vary across dominantly inherited Alzheimer's disease (DIAD) presenilin‐1 (PSEN1) mutation carriers. We investigated how mutation position relative to codon 200 (pre‐/postcodon 200) influences these pathologic features and dementia at different stages.METHODSIndividuals from families with known PSEN1 mutations (n = 393) underwent neuroimaging and clinical assessments. We cross‐sectionally evaluated regional Pittsburgh compound B‐positron emission tomography uptake, magnetic resonance imaging markers of SVD (diffusion tensor imaging‐based white matter injury, white matter hyperintensity volumes, and microhemorrhages), and cognition.RESULTSPostcodon 200 carriers had lower amyloid burden in all regions but worse markers of SVD and worse Clinical Dementia Rating® scores compared to precodon 200 carriers as a function of estimated years to symptom onset. Markers of SVD partially mediated the mutation position effects on clinical measures.DISCUSSIONWe demonstrated the genotypic variability behind spatiotemporal amyloidosis, SVD, and clinical presentation in DIAD, which may inform patient prognosis and clinical trials.Highlights Mutation position influences Aβ burden, SVD, and dementia. PSEN1 pre‐200 group had stronger associations between Aβ burden and disease stage. PSEN1 post‐200 group had stronger associations between SVD markers and disease stage. PSEN1 post‐200 group had worse dementia score than pre‐200 in late disease stage. Diffusion tensor imaging‐based SVD markers mediated mutation position effects on dementia in the late stage.
Cardiac Magnetic Resonance Imaging in Heart Transplant Recipients with Biopsy-Negative Graft Dysfunction
Anand, Senthil, Alnsasra, Hilmi , LeMond, Lisa , Shrivastava, Sanskriti , Rosenbaum, Andrew , Kobrossi, Semaan, Mohananey, Akanksha, Murphy, Katie , Kushwaha, Sudhir S. , Steidley, D. Eric , Clavell, Alfredo L. , Young, Phillip M. , Pereira, Naveen L. , Lemond, Lisa M, Steidley, David E, Clavell, Alfredo, Young, Phillip, Asleh, Rabea , Smith, Byron H.

Mayo Clinic

ESC Heart Failure | February 20, 2024 | Volume: 11 | Issue: 3 | Pages: 1594-1601

10.1002/ehf2.14681 | PMID 38379022 Get It

Abstract Aims Graft dysfunction (GD) after heart transplantation (HTx) can develop without evidence of cell- or antibody-mediated rejection. Cardiac magnetic resonance imaging (CMR) has an evolving role in detecting rejection; however, its role in biopsy-negative GD has not been described. This study examines CMR findings, evaluates outcomes based on CMR results, and seeks to identify the possibility of rejection missed through endomyocardial biopsy by using CMR in HTx recipients with biopsy-negative GD. Methods and results HTx recipients with GD [defined as a decrease in left ventricular ejection fraction (LVEF) by &gt;5% and LVEF &lt; 50%] in the absence of rejection by biopsy or allograft vasculopathy and who underwent CMR were included in the study. The primary outcome was a composite of all-cause mortality, re-transplantation, or persistent LVEF &lt; 50%. Overall, 34 HTx recipients developed biopsy-negative GD and underwent CMR. Left ventricular late gadolinium enhancement (LGE) on CMR was observed in 16 patients with two distinct patterns: diffuse epicardial (n = 13) and patchy (n = 3) patterns. Patients with LGE developed GD later after HTx [4 (1.4–6.8) vs. 0.8 (0.3–1.2) years, P &lt; 0.001], were more often symptomatic (88% vs. 56%, P = 0.06), and had greater haemodynamic derangement (pulmonary capillary wedge pressure: 19 ± 7 vs. 13 ± 3 mmHg, P = 0.002) as compared with those without LGE. No significant difference was observed in the primary composite outcome between patients with LGE and those without LGE (50% vs. 38% of patients with events, P = 0.515). During a median follow-up of 3.8 years, mean LVEF improved similarly in the LGE-negative (37–55%) and LGE-positive groups (32–55%) (P = 0.16). Conclusions Biopsy-negative GD occurs with and without LGE when assessed by CMR, indicative of possible rejection/inflammation occurring only in a subset of patients. Irrespective of LGE, LVEF improvement occurs in most GD patients, suggesting that other neurohormonal or immunomodulatory mechanisms may also contribute to GD development.
The past, present, and future of the brain imaging data structure (BIDS)
Markiewicz, Christopher J. , Bansal, Shashank , Bénar, Christian , Bertazzoli, Giacomo , Bhogawar, Suyash , Blair, Ross , Brooks, Teon L , Calhoun, Vince D. , Castelli, Filippo Maria , D’Ambrosio, Sasha , Hollander, Gilles de , Vega, Alejandro de la , Delorme, Arnaud , Earl, Eric , Feingold, Franklin , Flandin, Guillaume, Galassi, Anthony , Gallitto, Giuseppe , Ganz, Melanie , Gholam, James , Ghosh, Satrajit , Guidali, Giacomo , Handwerker, Daniel A. , Hardcastle, Nell , Innis, Robert B. , Ioanas, Horea-Ioan , Jahn, Andrew , Karakuzu, Agâh , Kincses, Bálint , Lau, Jonathan C. , Li, Xiangrui , Meisler, Steven L. , Mikkelsen, Mark E. , Nichols, Thomas E. , Ort, Eduard , Park, Patrick J., Pawlik, Mateusz , Pestilli, Franco , Pollonini, Luca , Rizzo, Gaia , Robbins, Kay A. , Rockhill, Alexander P. , Rogers, Christine , Rokem, Ariel , Rorden, Chris , Routier, Alexandre , Saborit-Torres, Jose Manuel , Schirner, Michael , Smith, Robert E. , Sprenger, Julia , Szinte, Martin , Thomas, Adam G. , Torabian, Sajjad, Voytek, Bradley , Calhoun, Vince D. , Poldrack, Russell A. , Appelhoff, Stefan , Ashar, Yoni K. , Auer, Tibor , Baillet, Sylvain , Beltrachini, Leandro , Bortoletto, Marta , Boudreau, Mathieu , Clement, Patricia , Cohen, Alexander L. , Cohen-Adad, Julien , Iglesia-Vayá, María de la , Devinsky, Orrin , Draschkow, Dejan , Duff, Eugene Paul , DuPré, Elizabeth , Estéban, Oscar , Gau, Rémi , Ghosh, Satrajit S , Giacomel, Alessio , Gillman, Ashley , Gleeson, Padraig , Gramfort, Alexandre , Guay, Samuel , Halchenko, Yaroslav O. , Herholz, Peer , Hermes, Dora , Honey, Christopher John , Keator, David B. , Kiar, Gregory , Laird, Angela R. , Lazari, Alberto , Legarreta, Jon Haitz , Li, Adam , Love, Bradley C. , Lu, Hanzhang , Marcantoni, Eleonora , Maumet, Camille , Mazzamuto, Giacomo , Mutsaerts, Henk , Nikolaidis, Aki , Nilsonne, Gustav , Niso, Guiomar , Nørgaard, Martin Agge , Okell, Thomas W. , Oostenveld, Robert , Pernet, Cyril R , Petr, Jan , Phillips, Christophe L. M. , Poline, Jean‐Baptiste , Raamana, Pradeep Reddy , Ritter, Petra , Salo, Taylor , Spisák, Tamás , Swann, Nicole C. , Takerkart, Sylvain , Thirion, Bertrand , Varoquaux, Gaël , Welzel, Julius , Wilson, Martin , Yarkoni, Tal , Gorgolewski, Krzysztof J.

Mayo Clinic

Imaging Neuroscience | February 20, 2024 | Volume: 2 | Issue: No issue available | Pages: No page available

10.1162/imag_a_00103 | PMID 39308505 Get It

Abstract The Brain Imaging Data Structure (BIDS) is a community-driven standard for the organization of data and metadata from a growing range of neuroscience modalities. This paper is meant as a history of how the standard has developed and grown over time. We outline the principles behind the project, the mechanisms by which it has been extended, and some of the challenges being addressed as it evolves. We also discuss the lessons learned through the project, with the aim of enabling researchers in other domains to learn from the success of BIDS.
Interferons in the treatment of myeloproliferative neoplasms
Vachhani, Pankit , Mascarenhas, John , Bose, Prithviraj , Yacoub, Abdulraheem , Palmer, Jeanne , Rampal, Raajit K. , Verstovšek, Srđan , Palmer, Jeanne M , Verstovsek, Srdan , Bose, Prithviraj , Mascarenhas, John , Hobbs, Gabriela , Gerds, Aaron T. , Masárová, Lucia , Kuykendall, Andrew , Mesa, Ruben A.

Mayo Clinic

Therapeutic Advances in Hematology | February 20, 2024 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/20406207241229588 | PMID 38380373 Get It

Interferons are cytokines with immunomodulatory properties and disease-modifying effects that have been used to treat myeloproliferative neoplasms (MPNs) for more than 35 years. The initial use of interferons was limited due to difficulties with administration and a significant toxicity profile. Many of these shortcomings were addressed by covalently binding polyethylene glycol to the interferon structure, which increases the stability, prolongs activity, and reduces immunogenicity of the molecule. In the current therapeutic landscape, pegylated interferons are recommended for use in the treatment of polycythemia vera, essential thrombocythemia, and primary myelofibrosis. We review recent efficacy, molecular response, and safety data for the two available pegylated interferons, peginterferon alfa-2a (Pegasys) and ropeginterferon alfa-2b-njft (BESREMi). The practical management of interferon-based therapies is discussed, along with our opinions on whether to and how to switch from hydroxyurea to one of these therapies. Key topics and questions related to use of interferons, such as their safety and tolerability, the significance of variant allele frequency, advantages of early treatment, and what the future of interferon therapy may look like, will be examined. Pegylated interferons represent an important therapeutic option for patients with MPNs; however, more research is still required to further refine interferon therapy.